Key statistics
As of last trade, ACADIA Pharmaceuticals Inc (DR6:DUS) traded at 16.43, 25.80% above the 52 week low of 13.06 set on Oct 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.37 |
---|---|
High | 16.43 |
Low | 16.37 |
Bid | 16.46 |
Offer | 16.72 |
Previous close | 16.37 |
Average volume | 31.14 |
---|---|
Shares outstanding | 165.88m |
Free float | 164.47m |
P/E (TTM) | 22.78 |
Market cap | 2.93bn USD |
EPS (TTM) | 0.7753 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 08:31 GMT.
More ▼
Press releases
- Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
- Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
- Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Ryan Reynolds Announces More to Parkinson’s® Campaign
More ▼